The anti-tumor effect of Runfei Yishen drink on lung cancer bearing rats and its impact on tumor immune microenvironment

doi:10.11958/20230694

Abstract

Abstract:

Objective To explore the anti-tumor effect of Runfei Yishen drink on lung cancer bearing rats and its impact on tumor immune microenvironment. Methods A lung cancer rat model was established by injecting Lewis lung cancer cells subcutaneously into right quarter rib of rats, and model rats were randomly divided into the model group, the low dose Runfei Yishen drink (Runfei Yishen drink-L) group (3.5 g/kg), the medium dose Runfei Yishen drink (Runfei Yishen drink-M) group (7.0 g/kg), the high dose Runfei Yishen drink (Runfei Yishen drink-H) group (14.0 g/kg) and the positive drug group (6 mg/kg cisplatin). Normal rats were used as the control group. After the intervention, lung index, spleen index and tumor inhibition rate of rats were calculated in each group. Blood samples were collected, and serum levels of transforming growth factor-β (TGF-β), interleukin (IL)-2 and interferon γ (IFN-γ) were detected by ELISA. T lymphocyte subsets in peripheral blood were detected by flow cytometry. Lung tumor tissue was isolated and its pathological changes were detected by HE staining. The expression levels of programmed death receptor 1 (PD-L1) and B-lymphoblastoma-2 (Bcl-2) were detected by Western blot assay. Results Compared with the control group, the pathological injury of the model group was serious, the lung index, TGF-β, CD8⁺, and the expression levels of PD-L1 and Bcl-2 were increased, and the spleen index, IL-2, IFN-γ, CD3⁺, CD4⁺ and CD4⁺/CD8⁺ were decreased (P<0.05). Compared with the model group, the pathological damage of the Runfei Yishen drink-L group, the Runfei Yishen drink-M group and the Runfei Yishen drink-H group gradually improved, the lung index, tumor weight, CD8⁺, TGF-β and the expression levels of PD-L1 and Bcl-2 were decreased, and spleen index, IL-2, IFN-γ, CD3⁺, CD4⁺ and CD4⁺/CD8⁺ were increased (P<0.05). There were no significant differences in above indexes between the Runfei Yishen drink-H group and the positive drug group (P>0.05). Conclusion Runfei Yishen drink can obviously inhibit tumor growth and improve the tumor immune microenvironment in lung cancer bearing rats.

Key words: carcinoma, Lewis lung, tumor microenvironment, Runfei Yishen drink, tumor suppression

CLC Number:

R734.2

Figures/Tables 7

References 23

[1]	GUO H, ZHANG J, QIN C, et al. Biomarker-targeted therapies in non-small cell lung cancer:current status and perspectives[J]. Cells, 2022, 11(20):3200. doi:10.3390/cells11203200.
[2]	WU B, XUE X, LIN S, et al. LncRNA LINC00115 facilitates lung cancer progression through miR-607/ITGB1 pathway[J]. Environ Toxicol, 2022, 37(1):7-16. doi:10.1002/tox.23367.
[3]	陈健, 孟晶晶, 赵永生, 等. 胸腔镜微创切除非小细胞肺癌患者术后复发与转移的影响因素分析[J]. 中国中西医结合外科杂志, 2023, 29(3):343-347.
	CHEN J, MENG J J,ZHA 0 Y S, et al. Influencing factors of postoperative recurrence and metastasis in patients with non-small cell lung cancer undergoing minimally invasive thoracoscopic resection[J]. Chinese Journal of Surgery of Integrated Traditional and Western Medicine, 2023, 29(3):343-347. doi:10.3969/j.issn.1007-6948.2023.03.011.
[4]	吴琳, 张渭波, 行艳丽, 等. 阳和汤对Lewis肺癌荷瘤小鼠的抑瘤效应及肿瘤免疫微环境影响的实验研究[J]. 中国医药导报, 2021, 18(25):26-31.
	WU L, ZHANG W B, HANG Y L, et al. Experimental study on antitumor effect and the effect of tumor immune microenvironment of Yanghe Decoction on Lewis lung cancer mice[J]. China Medical Herald, 2021, 18(25):26-31.
[5]	丁念, 卢丽君, 刘陈, 等. 润肺益肾饮对慢性阻塞性肺疾病稳定期患者肺功能及生活质量的影响[J]. 中国中医急症, 2016, 25(4):709-711.
	DING N, LU L J, LIU C, et al. Influence of Runfei Yishen Decoction on pulmonary function and quality of life in patients with COPD stabilization[J]. Journal of Emergency in Traditional Chinese Medicine, 2016, 25(4):709-711. doi:10.3969/j.issn.1004-745X.2016.04.048.
[6]	FRIDMAN W H, ZITVOGEL L, SAUTÈS-FRIDMAN C, et al. The immune contexture in cancer prognosis and treatment[J]. Nat Rev Clin Oncol, 2017, 14(12):717-734. doi:10.1038/nrclinonc.2017.101.
[7]	俞文峰, 牛越群, 吕望, 等. 中医药在肿瘤免疫微环境中的作用[J]. 浙江中西医结合杂志, 2019, 29(8):695-698.
	YU W F, NIU Y Q, LYU W, et al. The role of traditional Chinese medicine in tumor immune microenvironment[J]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine, 2019, 29(8):695-698. doi:10.3969/j.issn.1005-4561.2019.08.030.
[8]	刘建波, 李白羽, 柯善保, 等. 虫草素抑制JAK2/STAT3通路减轻肺癌大鼠放射性免疫功能损伤[J]. 肿瘤防治研究, 2021, 48(11):994-998.
	LIU J B, LI B Y, KE S B, et al. Cordycepin attenuates immune function injury in a rat model of lung cancer after radiotherapy by inhibiting JAK2/STAT3 pathway[J]. Cancer Research on Prevention and Treatment, 2021, 48(11):994-998. doi:10.3971/j.issn.1000-8578.2021.21.0094.
[9]	黄继汉, 黄晓晖, 陈志扬, 等. 药理试验中动物间和动物与人体间的等效剂量换算[J]. 中国临床药理学与治疗学, 2004, 9(9):1069-1072.
	HUANG J H, HUANG X H, CHEN Z Y, et al. Dose conversion among different animals and healthy volunteers in pharmacological study[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(9):1069-1072. doi:10.3969/j.issn.1009-2501.2004.09.026.
[10]	项磊, 苏明君, 马志超, 等. 扶正抑瘤汤对肺癌荷瘤小鼠肿瘤生长,免疫微环境的影响[J]. 世界中西医结合杂志, 2021, 16(8):1447-1452.
	XIANG L, SU M J, MA Z C, et al. Effect of Fuzheng Yiliu Decoction on tumor growth and immune microenvironment in nude mice bearing lung cancer[J]. World Journal of Integrated Traditional and Western Medicine, 2021, 16(8):1447-1452. doi:10.13935/j.cnki.sjzx.210814.
[11]	BADE B C, DELA CRUZ C S. Lung Cancer 2020:Epidemiology,Etiology,and Prevention[J]. Clin Chest Med, 2020, 41(1):1-24. doi:10.1016/j.ccm.2019.10.001.
[12]	LIU J H, LI C, CAO L, et al. Cucurbitacin B regulates lung cancer cell proliferation and apoptosis via inhibiting the IL-6/STAT3 pathway through the lncRNA XIST/miR-let-7c axis[J]. Pharm Biol, 2022, 60(1):154-162. doi:10.1080/13880209.2021.2016866.
[13]	SU X L, WANG J W, CHE H, et al. Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer[J]. Chin Med J (Engl), 2020, 133(24):2987-2997. doi:10.1097/CM9.0000000000001141.
[14]	于弘, 胡倩, 周光飚. 肺癌中医证型与用药规律的研究[J]. 中成药, 2022, 44(7):2273-2278.
	YU H, HU Q, ZHOU G B. Study on traditional Chinese medicine syndromes and medication rules of lung cancer[J]. Chinese Patent Medicine, 2022, 44(7):2273-2278. doi:10.3969/j.issn.1001-0528.2022.07.036.
[15]	张文菲. 润肺益肾饮对慢性肾脏病肾性贫血的临床疗效观察[J]. 中西医结合心血管病电子杂志, 2019, 7(25):61-62.
	ZHANG W F. Observation on the clinical effect of Runfei Yishenyin on chronic kidney disease with renal anemia[J]. Cardiovascular Disease Journal of Integrated Traditional Chinese and Western MedicineElectronic, 2019, 7(25):61-62.
[16]	刘涛, 吕奇, 陈小娟, 等. 润肺益肾饮对维持性血液透析脾肾两虚型患者微炎症的影响[J]. 中医药导报, 2020, 26(10):62-65.
	LIU T, LU Q, CHEN X J, et al. Effect of Runfei Yishen Decoction on microinflammation in maintenance hemodialysis patients with deficiency of spleen and kidney syndrome[J]. Guiding Journal of Traditional Chinese Medicine and Pharmacy, 2020, 26(10):62-65.
[17]	翟占强, 江立群, 朱佳, 等. 基于JAK/STAT通路EFhD2蛋白对肺癌大鼠T淋巴细胞免疫功能的调节作用研究[J]. 中国免疫学杂志, 2021, 37(14):1672-1676,1681.
	ZHAI Z Q, JIANG L Q, ZHU J, et al. Regulatory effect of EFhD2 protein based on JAK/STAT pathway on T lymphocyte immune function of lung cancer rats[J]. Chinese Journal of Immunology, 2021, 37(14):1672-1676,1681. doi:10.3969/j.issn.1000-484X.2021.14.002.
[18]	PANSY K, UHL B, KRSTIC J, et al. Immune regulatory processes of the tumor microenvironment under malignant conditions[J]. Int J Mol Sci, 2021, 22(24):13311. doi:10.3390/ijms222413311.
[19]	杨任华, 尹璇. 某营养复合物对荷瘤小鼠肿瘤生长及免疫功能的影响[J]. 预防医学, 2019, 31(10):1001-1006.
	YANG R H, YIN X. Effects of a nutritional complex on tumor growth and immune function in tumor-bearing mice[J]. Preventive Medicine, 2019, 31(10):1001-1006.
[20]	税璘, 刘明华, 税丕先, 等. 金钗石斛破壁粉对荷瘤小鼠肿瘤生长及免疫功能的影响[J]. 中国新药杂志, 2018, 27(16):1896-1901.
	SHUI L, LIU M H, SHUI P X, et al. Effects of Dendrobium nobile Lindl wall-broken powder on tumor growth and immune function of tumor-bearing mice[J]. Chinese Journal of New Drugs, 2018, 27(16):1896-1901.
[21]	ELIA G, FALLAHI P. Hepatocellular carcinoma and CXCR3 chemokines:a narrative review[J]. Clin Ter, 2017, 168(1):e37-e41. doi:10.7417/CT.2017.1980.
[22]	王宏君, 孙星星, 张润莲. 基于PI3K/Akt/NF-κB信号通路探讨升阳益胃汤对肺癌大鼠免疫力的影响[J]. 天津医药, 2023, 51(7):739-745.
	WANG H J, SUN X X, ZHANG R L. Study on the effect of Shengyang Yiwei Decoction on the immune function of rats with lung cancer based on PI3K/Akt/NF-κB signal pathway[J]. Tianjin Med J, 2023, 51(7):739-745. doi:10.11958/20221626.
[23]	朱虹, 刘单, 邓述恺. 顺铂通过激活细胞外信号调节激酶(ERK)通路促进A549人肺腺癌细胞PD-L1表达[J]. 细胞与分子免疫学杂志, 2021, 37(10):891-896.
	ZHU H, LIU S, DENG S K. Cisplatin promotes PD-L1 expression in A549 human lung adenocarcinoma cells via activating the ERK pathway[J]. Chinese Journal of Cellular and Molecular Immunology, 2021, 37(10):891-896. doi:10.13423/j.cnki.cjcmi.009253.

组别	肺指数	脾脏指数
对照组	2.45±0.25	4.99±0.51
模型组	6.54±0.67^a	1.52±0.16^a
润肺益肾饮-L组	4.51±0.46^b	2.16±0.22^b
润肺益肾饮-M组	3.37±0.34^bc	3.19±0.32^bc
润肺益肾饮-H组	2.51±0.26^bcd	4.25±0.43^bcd
阳性药组	2.49±0.25^bcd	4.31±0.44^bcd
F	164.201^＊	135.383^＊

组别	肺指数	脾脏指数
对照组	2.45±0.25	4.99±0.51
模型组	6.54±0.67^a	1.52±0.16^a
润肺益肾饮-L组	4.51±0.46^b	2.16±0.22^b
润肺益肾饮-M组	3.37±0.34^bc	3.19±0.32^bc
润肺益肾饮-H组	2.51±0.26^bcd	4.25±0.43^bcd
阳性药组	2.49±0.25^bcd	4.31±0.44^bcd
F	164.201^＊	135.383^＊

组别	TGF-β	IL-2	IFN-γ
对照组	32.15±3.24	10.58±1.07	47.68±3.06
模型组	88.67±8.88^a	5.26±0.53^a	18.42±1.56^a
润肺益肾饮-L组	65.24±6.55^b	6.88±0.65^b	25.67±2.13^b
润肺益肾饮-M组	48.37±4.84^bc	8.05±0.81^bc	31.52±2.35^bc
润肺益肾饮-H组	35.25±3.54^bcd	10.22±1.03^bcd	39.68±2.89^bcd
阳性药组	33.27±3.34^bcd	10.29±1.03^bcd	39.75±2.93^bcd
F	170.259^＊	61.736^＊	176.463^＊

组别	TGF-β	IL-2	IFN-γ
对照组	32.15±3.24	10.58±1.07	47.68±3.06
模型组	88.67±8.88^a	5.26±0.53^a	18.42±1.56^a
润肺益肾饮-L组	65.24±6.55^b	6.88±0.65^b	25.67±2.13^b
润肺益肾饮-M组	48.37±4.84^bc	8.05±0.81^bc	31.52±2.35^bc
润肺益肾饮-H组	35.25±3.54^bcd	10.22±1.03^bcd	39.68±2.89^bcd
阳性药组	33.27±3.34^bcd	10.29±1.03^bcd	39.75±2.93^bcd
F	170.259^＊	61.736^＊	176.463^＊

组别	CD3⁺/%	CD4⁺/%
对照组	64.27±3.44	47.18±2.21
模型组	42.15±1.22^a	13.42±1.75^a
润肺益肾饮-L组	48.25±1.78^b	35.24±1.82^b
润肺益肾饮-M组	56.24±2.55^bc	40.27±2.15^bc
润肺益肾饮-H组	61.27±2.88^bcd	45.54±2.17^bcd
阳性药组	61.34±2.89^bcd	45.66±2.21^bcd
F	113.705^＊	384.699^＊
组别	CD8⁺/%	CD4⁺/CD8⁺
对照组	17.15±1.52	2.76±0.22
模型组	30.29±2.85^a	0.44±0.09^a
润肺益肾饮-L组	25.15±2.11^b	1.41±0.11^b
润肺益肾饮-M组	21.15±2.01^bc	1.91±0.13^bc
润肺益肾饮-H组	17.52±1.61^bcd	2.64±0.19^bcd
阳性药组	17.22±1.65^bcd	2.66±0.13^bcd
F	71.162^＊	364.523^＊